Rubric Capital and David Rosen disclose 9.29% stake in Prothena (PRTA)
Rubric Capital Management LP and David Rosen have collectively disclosed a 9.29% stake in Prothena Corporation plc (PRTA), holding 5,000,000 Ordinary Shares with shared voting and dispositive power. This information comes from a Schedule 13G/A SEC filing, which also indicates that Rubric Capital Master Fund LP has rights to dividends or sale proceeds for over 5% of these shares. The reported ownership is based on 53,832,982 outstanding Ordinary Shares as of March 2, 2026.
Prothena (NASDAQ: PRTA) investors approve board, KPMG and executive pay
Prothena Corporation plc shareholders re-elected two directors, Shane M. Cooke and Dennis J. Selkoe, to the Board until 2029. They also ratified KPMG LLP as the independent registered public accounting firm for fiscal year 2026 and approved the compensation of the company's named executive officers in a non-binding advisory vote. The outcomes maintain the existing board structure, audit relationship, and executive pay framework.
Prothena Corp plc stock (IE00B91XRN20): Biotech investor focus amid pipeline updates
Prothena Corp plc, a clinical-stage biotech firm, continues to attract investor attention with its pipeline targeting neurodegenerative diseases like Alzheimer's and ALS. The company is advancing candidates like prasinezumab and birtamimab, focusing on misfolded proteins, and maintains a strong financial position, reducing immediate dilution risks. Prothena's presence on Nasdaq offers US investors direct access to its innovative therapies, which are strategically positioned in a competitive biotech landscape.
Number of shareholders of Prothena Corp. Plc – DUS:0PT
This article provides information about the number of shareholders of Prothena Corp. Plc (DUS:0PT), a biotechnology company listed on the Dusseldorf Stock Exchange. It focuses on offering financial data and market insights for the company.
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Prothena Corporation plc reported its latest quarterly results, with analysts now forecasting revenues of US$83.3m in 2026, a 44% increase year-over-year. Despite beating forecasts, analysts have become more bearish on revenue and earnings per share estimates, cutting EPS predictions significantly. However, the consensus price target remains unchanged at US$21.40, suggesting analysts don't expect a long-term impact on valuation despite the revised short-term outlook.
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Prothena Corporation plc recently reported its quarterly results, leading analysts to update their forecasts. Despite beating expectations, sentiment has become more bearish, with revenue and EPS estimates being cut. However, the consensus price target remains largely unchanged, suggesting analysts don't foresee a long-term impact on the company's valuation, and Prothena is still expected to experience significant revenue growth.
Prothena (PRTA) Heavy US$244 Million Annual Loss Tests Bullish Profitability Narratives
Prothena (PRTA) reported a significant annual net loss of US$244.1 million on only US$9.7 million in revenue for FY 2025, alongside fluctuating quarterly revenues and EPS losses. Despite analyst expectations for strong revenue and earnings growth, the company's losses have widened, challenging the bullish narrative that relies heavily on its pipeline progress and potential milestone payments. The article highlights the gap between the current financial performance and optimistic projections, emphasizing the dependence on successful trial outcomes for its partnered neurology and cardiology programs.
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
This article announces Prothena's third-quarter 2025 financial results and business highlights. It would typically cover key financial figures, progress on clinical trials, and any significant corporate developments from the quarter.
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
Prothena reported a net income of $32.7 million for the first quarter of 2026, a significant improvement from a net loss in the prior year, primarily driven by a $50 million milestone payment from Novo Nordisk for coramitug. The company updated its full-year 2026 net cash guidance, anticipating ending the year with approximately $273 million in cash. Prothena highlighted progress in its partnered clinical programs, including Fast Track designation for coramitug and promising updates on prasinezumab for Parkinson's disease, and announced a share repurchase program worth up to $100 million.
Prothena (PRTA) Price Target Increased by 37.50% to 16.83
The article reports that the price target for Prothena (PRTA) has been increased by 37.50% to 16.83. No further details about the company, the analysis, or the reasons for the target increase are available in the provided text.
Prothena Corporation plc (PRTA) Stock Analysis: Biotechnology Innovator with a 99.62% Potential Upside
Prothena Corporation plc (PRTA) is a biotechnology company focused on developing therapies for diseases caused by protein dysregulation, with a substantial potential upside of 99.62% according to current analyst ratings. Despite its early-stage financial metrics, including a negative P/E ratio and challenging revenue growth, the company is advancing several late-stage clinical trials for Parkinson's and transthyretin amyloidosis, supported by collaborations with pharmaceutical giants. Technical indicators suggest an oversold stock, presenting a potential buying opportunity for risk-tolerant investors looking for long-term growth in the biotech sector.
A $50M Novo milestone reshaped Prothena’s 2026 cash outlook
Prothena reported a Q1 2026 net income of $32.7 million, a significant increase from a net loss in Q1 2025, largely due to a $50 million milestone payment from Novo Nordisk for coramitug's Phase 3 enrollment and Fast Track designation. This payment has led Prothena to update its 2026 financial guidance, projecting a reduced net cash used in operating and investing activities and an increased year-end cash balance. The company also highlighted advancements in its partnered clinical programs for Parkinson's and Alzheimer's diseases and initiated a share repurchase program.
Prothena reports first quarter 2026 financial results and business highlights
Prothena (NASDAQ: PRTA) announced its first quarter 2026 financial results and provided business updates. These announcements typically cover key financial metrics, progress on clinical trials, and important corporate milestones achieved during the period. The report helps investors and stakeholders understand the company's performance and future outlook.
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
Prothena reported strong financial results for Q1 2026, driven by a $50 million milestone payment from Novo Nordisk for coramitug's Phase 3 enrollment. The company updated its full-year 2026 cash burn guidance, expecting to end the year with approximately $273 million in cash. Key business highlights included advancements in partnered clinical programs for Parkinson's and ATTR amyloidosis, as well as the completion of a Phase 1 study for PRX019.
Prothena (NASDAQ: PRTA) posts $32.7M Q1 profit and lifts 2026 cash outlook
Prothena (NASDAQ: PRTA) reported a first-quarter 2026 profit of $32.7 million, reversing a $60.2 million loss from the previous year, driven by a $50 million milestone payment from Novo Nordisk and reduced operating expenses. The company also improved its 2026 cash outlook, projecting lower net cash usage and a higher year-end cash balance of approximately $273 million. Prothena is advancing its clinical pipeline, including partnered programs for Parkinson's and Alzheimer's diseases, and has initiated a $100 million share repurchase program.
Prothena (Nasdaq:PRTA) - Stock Analysis
This article provides a detailed stock analysis of Prothena (Nasdaq: PRTA), a late-stage clinical biotechnology company, highlighting its financial health, growth forecasts, and recent news. Analysts currently view the stock as undervalued, with significant projected earnings growth, despite past revenue misses and share price volatility. Key developments include Fast Track Designation for coramitug, changes in leadership, and ongoing clinical trials for various neurodegenerative diseases.
(PRTA) Movement as an Input in Quant Signal Sets
This article analyzes Prothena Corporation Plc (NASDAQ: PRTA) using AI models, suggesting a near-term neutral sentiment but mid-to-long-term strength. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights an exceptional short setup targeting 14.0% downside with minimal risk.
Prothena announces Novo Nordisk obtains fast track designation from the US FDA for Coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy
Prothena announced that Novo Nordisk has received Fast Track designation from the U.S. FDA for coramitug (PRX004). This designation is for the treatment of ATTR amyloidosis with cardiomyopathy, a serious and life-threatening condition. The Fast Track program aims to expedite the development and review of drugs for serious or life-threatening conditions.
Prothena to Report First Quarter 2026 Financial Results on May 7
Prothena Corporation plc announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, after the close of U.S. financial markets. The company, a late-stage clinical biotechnology firm focused on neurodegenerative and rare peripheral amyloid diseases, will not host a conference call in conjunction with this financial report.
3 Growth Companies Insiders Are Eager To Hold
The article highlights three growth companies—Prothena (PRTA), Pattern Group (PTRN), and Equity Bancshares (EQBK)—that exhibit high insider ownership, signaling strong confidence from those closest to the business. These companies are poised for significant earnings and revenue growth, driven by strategic initiatives, leadership changes, and share repurchase programs, making them potentially appealing to investors. The U.S. market's overall growth and stability provide a favorable environment for such companies.
3 Growth Companies Insiders Are Eager To Hold
This article highlights three growth companies—Prothena (PRTA), Pattern Group (PTRN), and Equity Bancshares (EQBK)—with high insider ownership, indicating strong confidence in their future prospects. Despite varying market caps and operational focuses, all three show significant forecasted earnings and revenue growth, along with strategic initiatives and share repurchase programs, suggesting they may be undervalued or poised for strong performance.
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena announced that Novo Nordisk has received Fast Track Designation from the U.S. FDA for coramitug (PRX004), an amyloid depleter antibody for ATTR amyloidosis with cardiomyopathy (ATTR-CM). This designation aims to expedite the development and review of coramitug, which is currently in Phase 3 clinical trials and addresses a significant unmet medical need for patients with this life-threatening disease. Coramitug is designed to clear existing amyloid deposits and prevent further organ deposition, potentially offering a new therapeutic approach for ATTR-CM.
Liquidity Mapping Around (PRTA) Price Events
Prothena Corporation Plc (NASDAQ: PRTA) is showing a near-term neutral sentiment amidst mid and long-term strength, with support being tested. An exceptional 56.7:1 risk-reward setup targets a 16.1% gain versus a 0.3% risk. AI models have generated three distinct trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy.
PRTA SEC Filings - Prothena 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Prothena Corporation plc (NASDAQ: PRTA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. It features AI-powered summaries to simplify understanding of these regulatory documents for investors. The article highlights recent 8-K filings detailing financial results, program discontinuations, collaboration developments with partners like Novo Nordisk, and governance updates.
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts
Prothena Corporation plc (NASDAQ:PRTA) has received a consensus "Hold" rating from eleven analysts, with an average 12-month price target of $21.67. The company's stock currently trades around $10.79, and institutional ownership stands at approximately 97.08%. Prothena, a clinical-stage biotechnology company focusing on neurodegenerative and rare diseases, reported Q4 earnings per share of -$0.44, beating estimates, but revenue missed expectations.
Prothena Corp plc stock (IE00B91XRN20): Why does its biotech pipeline matter more now for investors?
Prothena Corp plc (IE00B91XRN20) is a clinical-stage biotechnology company focused on developing therapies for protein misfolding diseases like Alzheimer's and amyloidosis. Its pipeline, including lead candidate birtamimab for AL amyloidosis and prasinezumab for Parkinson's in partnership with Roche, targets significant unmet medical needs. The company's strategy involves proprietary technologies, partnerships with big pharma, and a lean operational model, positioning it for potential high returns if clinical milestones are met.
Prothena Corp plc stock (IE00B91XRN20): Why does its biotech pipeline matter more now for investors?
Prothena Corp plc is a clinical-stage biotechnology company focusing on therapies for neurodegeneration and amyloidosis, targeting diseases like Alzheimer's and AL amyloidosis. The company's pipeline, including lead candidate birtamimab and partner asset prasinezumab, leverages proprietary technologies to address significant unmet medical needs. With a strategic emphasis on partnerships and a lean operating model, Prothena aims to deliver high returns to investors through potential blockbuster drug approvals, especially for its Nasdaq-listed ADR (PRTA).
Prothena Announces Leadership Team Updates
Prothena Corporation plc has announced key leadership team updates, promoting Annie Kingston to Chief Strategy Officer and Michael Isaacs to General Counsel and Corporate Secretary. These changes aim to support the company's growth strategy, partnered clinical programs, and wholly-owned preclinical programs, while also enhancing legal oversight. The company emphasizes its commitment to driving strategic priorities and exploring partnerships in the biotechnology industry.
Prothena (NASDAQ: PRTA) awards 100,000 stock options to Chief Strategy Officer
Prothena (NASDAQ: PRTA) has granted its Chief Strategy Officer, Anne Evans Kingston, 100,000 stock options with an exercise price of $10.50 per share. These options are set to expire on April 10, 2036, and will vest over four years, with 25% vesting on April 10, 2027, and the remainder vesting monthly thereafter, contingent on her continued employment. This transaction is a compensation-related grant and not an open-market purchase or sale of shares.
Prothena (PRTA) Chief Strategy Officer reports 66,942 shares and option grants
Prothena Corp Public Ltd Co's Chief Strategy Officer, Anne Evans Kingston, has filed an initial ownership report revealing holdings of 66,942 Ordinary Shares and several employee stock options. The options cover 5,000 shares at $53.81, 3,000 shares at $30.30, and 14,080 shares at $14.95, with expiration dates ranging from 2033 to 2035. These option grants vest 25% initially and then in equal monthly installments over four years, contingent on her continued employment with the company.
Prothena Announces Leadership Team Updates
Prothena Corporation plc announced leadership team changes, promoting Annie Kingston to Chief Strategy Officer and Michael Isaacs to General Counsel and Corporate Secretary. Ms. Kingston will focus on growth strategy and Mr. Isaacs will oversee legal functions, succeeding Michael Malecek. These appointments aim to strengthen the company's focus on clinical programs, preclinical investments, and strategic collaborations.
Prothena Announces Leadership Team Updates
Prothena Corporation plc announced key leadership team updates, promoting Annie Kingston to Chief Strategy Officer and Michael Isaacs to General Counsel and Corporate Secretary. These changes are aimed at strengthening the company's growth strategy and legal functions as it continues to advance its preclinical and clinical programs. Mr. Isaacs will succeed Michael Malecek, who is departing in June.
Prothena promotes Kingston, Isaacs to leadership roles
Prothena Corporation plc announced leadership changes, promoting Annie Kingston to Chief Strategy Officer and Michael Isaacs to General Counsel and Corporate Secretary. These appointments are effective immediately for Kingston and in June for Isaacs, positioning them on the company's leadership team. The company, a late-stage clinical biotechnology firm, also reported a recent milestone payment from Novo Nordisk and a $100 million share repurchase program.
Prothena Corporation Announces Leadership Team Updates to Support Pipeline Development
Prothena Corporation plc, a biotechnology company focusing on neurodegenerative and rare peripheral amyloid diseases, has announced immediate updates to its leadership team. These changes are intended to align leadership roles with the company's strategic priorities for pipeline development and strengthen its organizational structure for future growth. While specific details about the individuals and their new roles were not disclosed, Prothena emphasized its commitment to advancing innovative treatments.
PRTA Stock Price, Quote & Chart | PROTHENA CORP PLC (NASDAQ:PRTA)
This article provides a detailed stock overview for Prothena Corp. Plc (NASDAQ: PRTA), including its current price, historical performance, key statistics, and analyst forecasts. The company is a clinical-stage neuroscience firm focusing on therapies for devastating diseases, with a pipeline addressing conditions like Alzheimer's, Parkinson's, and various amyloidosis types. While its technical rating is 8/10, its fundamental rating stands at 4/10, with analysts predicting a significant price increase and strong EPS and revenue growth for the next year.
Prothena promotes Kingston, Isaacs to leadership roles By Investing.com
Prothena Corporation plc has announced key leadership changes, promoting Annie Kingston to Chief Strategy Officer and Michael Isaacs to General Counsel and Corporate Secretary. These appointments aim to strengthen the company's growth strategy and corporate legal functions. The company, a late-stage clinical biotechnology firm, continues to advance its pipeline for neurodegenerative diseases and has recently received a significant milestone payment and authorized a share repurchase program.
PRTA Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes the financial performance of Prothena Corporation PLC (PRTA), focusing on its revenue breakdown, profitability margins, and a comparison with competitors. PRTA boasts a 100.00% gross margin but shows significant negative operating and net margins and a negative Return on Equity, indicating challenges in converting operations into shareholder value. Despite these profitability issues, PRTA, with a market capitalization of $573.32M, maintains a leading position among competitors like CBIO and KYTX.
Prothena Corp plc Stock: Clinical Milestones and Strategic Focus in Biotechnology Drive Investor Int
Prothena Corp plc (PRTA) is gaining investor interest due to its advancements in neurodegenerative disease treatments, particularly for conditions like Alzheimer's and Parkinson's. The company leverages proprietary technologies and strategic partnerships with major pharmaceutical companies like Roche and Novo Nordisk. Key pipeline candidates like birtamimab for AL amyloidosis and coramitug for neurodegenerative conditions are progressing through late-stage clinical trials, attracting North American investors seeking biotech exposure.
PRTA Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Prothena Corporation PLC (PRTA). It highlights a "Strong Buy" technical sentiment based on various indicators, including moving averages and momentum oscillators. Key support and resistance levels are identified, along with an assessment of the stock's performance relative to its moving averages and RSI status.
Prothena Corp plc Stock: Clinical Milestones and Strategic Focus in Biotechnology Drive Investor Int
Prothena Corp plc, a NASDAQ-listed biotech firm, is gaining investor interest due to its advancements in neurodegenerative disease treatments, strategic partnerships, and clinical milestones. The company focuses on protein misfolding disorders, leveraging proprietary technologies and collaborations with major players like Roche and Novo Nordisk. Progress in its pipeline, including birtamimab for AL amyloidosis and coramitug for neurodegenerative conditions, demonstrates its potential for high returns for North American investors while acknowledging inherent risks in biotech investing.
PRTA Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for PRTA, highlighting past quarterly results and future forecasts. It details revenue and EPS estimates for upcoming quarters, analyst revisions, and the historical stock price reactions around earnings reports. The piece also includes a summary of the sentiment from Prothena Corporation PLC's Q4 2025 earnings call, indicating mixed feelings among investors.
Understanding Momentum Shifts in (PRTA)
This article analyzes Prothena Corporation Plc (PRTA) using AI models, identifying a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It presents three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis for support and resistance levels. The analysis highlights a significant 56.7:1 risk-reward short setup, signaling potential downside.
JPMorgan Chase & Co. Buys 608,814 Shares of Prothena Corporation plc $PRTA
JPMorgan Chase & Co. significantly increased its stake in Prothena Corporation plc, purchasing an additional 608,814 shares, bringing its total holding to 735,765 shares valued at approximately $7.18 million. Despite this institutional interest, Prothena remains unprofitable, reporting an EPS of -$0.44 against significantly lower-than-expected revenue. Analyst ratings for the biotechnology company are mixed, with a consensus "Hold" rating and a target price of $21.67.
When Can We Expect A Profit From Prothena Corporation plc (NASDAQ:PRTA)?
Prothena Corporation plc, a late-stage clinical biotechnology company, is anticipated to reach profitability by 2028, according to industry analysts. The company is expected to incur a final loss in 2027 before generating positive profits of US$1.4 million in 2028, requiring an aggressive annual growth rate of 80%. A notable aspect of Prothena's financial position is its debt-free balance sheet, which is uncommon for a loss-making biotech company and reduces investment risk.
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts
MarketBeat reports that Prothena Corporation plc (NASDAQ:PRTA) has received a consensus "Hold" rating from eleven analysts, with an average 1-year price target of $21.67. Institutions own 97.08% of the stock, and the company recently reported a slight EPS beat despite being unprofitable, with very negative net margins and return on equity. Prothena is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and rare diseases.
Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet
Wall Street analysts project a potential 120.19% surge for Prothena (PRTA), with a mean price target of $20.5 despite a significant standard deviation in estimates. While impressive price targets often mislead, analysts' increasing optimism about the company's earnings and a Zacks Rank #2 (Buy) suggest a potential upside. Investors are advised to use price targets as a starting point for further research, exercising skepticism due to potential biases.
Prothena (NASDAQ:PRTA) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened
Prothena (NASDAQ:PRTA) shares have fallen below their 200-day moving average, trading as low as $8.76 on Monday with a 200-day moving average of $9.56. Analysts have a consensus "Hold" rating for the stock with an average target price of $21.67, and the company recently reported quarterly earnings that beat consensus estimates. Institutional investors and hedge funds own a significant portion of the company's stock, with several making recent adjustments to their holdings.
Prothena Corp plc stock gains spotlight as partners Roche and Bristol-Myers Squibb showcase key clin
Prothena Corp plc is gaining increased investor attention after its partners, Roche and Bristol-Myers Squibb, presented promising clinical data for prasinezumab (Parkinson's) and BMS-986446 (Alzheimer's) at the AD/PD 2026 conference. This highlights Prothena's advancing pipeline in neurodegenerative diseases, driven by strategic partnerships that de-risk development and provide a diversified asset base. The company's partnership model and pipeline progress make it an attractive consideration for DACH investors seeking defensive growth in the biotech sector.
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
Prothena Corporation plc announced that its partners, Roche and Bristol Myers Squibb, presented clinical updates on investigational treatments for Parkinson’s and Alzheimer’s diseases at the AD/PD™ 2026 conference. Roche presented data on prasinezumab, suggesting potential disease-modifying efficacy and sustained effects in slowing Parkinson's progression. Bristol Myers Squibb shared safety and pharmacokinetic data for BMS-986446, a potential Alzheimer's treatment, showing it was well-tolerated.
Prothena Corp plc stock faces pressure amid biotech volatility and pipeline updates
Prothena Corp plc's stock is experiencing pressure due to biotech market volatility and ongoing pipeline developments, with shares trading around $10.39 on NASDAQ. The company, focused on protein misfolding diseases, is advancing key candidates like birtamimab for AL amyloidosis and collaborating on ATTR amyloidosis therapies. Despite analyst 'Hold' ratings and financial challenges common to development-stage biotechs, successful clinical readouts in its amyloidosis pipeline could offer significant upside, appealing to investors in the neurodegeneration sector.
